News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Jun 27, 2019
- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...
-
Jun 5, 2019
- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK...
-
Jun 4, 2019
- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief...
-
Jun 3, 2019
- Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findings and possible next steps for SRA737 - - Sierra reported SRA737...
-
Jun 1, 2019
- Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data...
-
May 28, 2019
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...
-
May 15, 2019
- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...
-
May 8, 2019
Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...
-
May 6, 2019
Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...
-
Apr 3, 2019
- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA),...